Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Amgen lifts 2023 revenue forecast, Q3 earnings beat estimates

Published Oct 31, 2023 03:01PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters.
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

Shares of Amgen (NASDAQ:AMGN) rose 3% in premarket trading Today after the biopharmaceutical company revised its 2023 revenue forecast upwards from $26.6B-$27.4B to a range of $28B-$28.4B, significantly outperforming analysts' predictions. The firm also adjusted its expected EPS for 2023 to be between $18.20-$18.80, surpassing both its previous guidance and analysts' estimate of $18.26.

For the third quarter of 2023, the company reported a top-line growth of 4% year-over-year (Y/Y), taking total revenues to $6.9B. However, this fell short of Wall Street estimates due to a 6% Y/Y decline in sales of its top-selling drug Enbrel, attributed to unfavorable changes in estimated sales deductions.

Despite these challenges, Amgen's bottom-line performance improved with a 6% increase in adjusted EPS to $4.96, beating market expectations. The company's operating expenses grew by 4%, and its cost of sales margin increased by 1.3 percentage points. Research and development expenses dropped by 2%, reflecting lower spending in research and early pipeline, offset by higher spending in later-stage clinical programs and marketed products.

Amgen's Q3 2023 free cash flow stood at $2.5B, marking a decrease from $2.8B in Q3 2022.

The company also reported that it is preparing for a $650 million impairment charge resulting from the termination of AMG 340, an experimental prostate cancer treatment.

Despite the mixed results and impending impairment charge, AMGN stock holds a Moderate Buy consensus among analysts, indicating cautious optimism about the company's future performance.

InvestingPro Insights

InvestingPro's real-time data and tips provide valuable insights into Amgen's performance and potential. The company's market cap stands at an impressive 135.13B USD, and with a P/E Ratio of 16.82, it offers an attractive valuation for investors. The company's revenue growth for Q2 2023 is 0.75%, indicating a steady increase in sales.

InvestingPro Tips highlight Amgen's high earnings quality, with free cash flow consistently exceeding net income. This is evident in the company's Q3 2023 free cash flow of $2.5B. The company is also known for its high return on invested capital and consistently increasing earnings per share, which aligns with its revised EPS for 2023.

Amgen has a strong track record of raising its dividend for 13 consecutive years, making it a potentially good pick for income-focused investors. It's also worth noting that the stock generally trades with low price volatility, offering a relatively stable investment option.

InvestingPro has numerous additional tips available for Amgen, providing in-depth insights into the company's performance and potential. These tips can be a valuable resource for investors seeking to make informed decisions about their investments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Amgen lifts 2023 revenue forecast, Q3 earnings beat estimates

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email